Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · lung-landscapes@6

C3N-00738

— · cohortMD2

595cdcc2-c24d-50bf-af9f-a8c4818545f2

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
cohortMD2
subtype
cohortMD2
age_years
70.88569473

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • TNFA_SIGNALING_VIA_NFKB+0.570
  • TGF_BETA_SIGNALING+0.500
  • ANDROGEN_RESPONSE+0.430
  • ANGIOGENESIS+0.430
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.430
  • IL2_STAT5_SIGNALING+0.430
  • INFLAMMATORY_RESPONSE+0.430
  • CHOLESTEROL_HOMEOSTASIS+0.420
  • PANCREAS_BETA_CELLS+0.420
  • MYOGENESIS+0.410

Top 10 suppressed

  • E2F_TARGETS-0.670
  • G2M_CHECKPOINT-0.570
  • MYC_TARGETS_V1-0.490
  • MYC_TARGETS_V2-0.490
  • INTERFERON_ALPHA_RESPONSE-0.370
  • DNA_REPAIR-0.360
  • MITOTIC_SPINDLE-0.320
  • GLYCOLYSIS-0.280
  • OXIDATIVE_PHOSPHORYLATION-0.230
  • NOTCH_SIGNALING-0.170

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR8613813
breast-umap@18
—D0.918
2TCGA-BH-A0BO-01A-23R-A12D-07
breast-umap@18
—A0.899
3TCGA-A2-A0EO-01A-11R-A034-07
breast-umap@18
—A0.898
4SRR23303755
bladder-landscape@3
——0.892
5SRR25043632
head-neck@1
——0.887
6SRR23303737
bladder-landscape@3
——0.886
7SRR8613755
breast-umap@18
—F0.878
8C3N-00545
lung-landscapes@6
—cohortA10.872
920060059.TNBC
breast-umap@18
—F0.872
10DRR168604
bladder-landscape@3
——0.870

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 36 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
TNFA_SIGNALING_VIA_NFKB0.570Inavolisib— uncovered
TGF_BETA_SIGNALING0.500Inavolisib— uncovered
ANDROGEN_RESPONSE0.430Inavolisib— uncovered
ANGIOGENESIS0.430Remibrutinib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.430Inavolisib— uncovered
IL2_STAT5_SIGNALING0.430Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.430Idelalisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.420Remibrutinib— uncovered
PANCREAS_BETA_CELLS0.420Cobimetinib— uncovered
MYOGENESIS0.410Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.400Inavolisib— uncovered
COAGULATION0.380Binimetinib— uncovered
KRAS_SIGNALING_UP0.380Inavolisib— uncovered
UV_RESPONSE_DN0.360Inavolisib— uncovered
COMPLEMENT0.350Inavolisib— uncovered
APOPTOSIS0.310Idelalisib— uncovered
HEDGEHOG_SIGNALING0.300Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.300Inavolisib— uncovered
ALLOGRAFT_REJECTION0.290Idelalisib— uncovered
BILE_ACID_METABOLISM0.250Inavolisib— uncovered